A novel human papillomavirus identified in epidermodysplasia verruciformis

British Journal of Dermatology

Volumn 136, Issue 4, 1997, Pages 587-591

  Harris, A J ^a,c   Purdie, K ^b   Leigh, I M ^b   Proby, C ^b   Burge, S ^a  

^a STOKE MANDEVILLE HOSPITAL   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CRYOSURGERY; EPIDERMODYSPLASIA VERRUCIFORMIS; HISTOPATHOLOGY; HUMAN; MALE; PAPILLOMA VIRUS; PRIORITY JOURNAL; RISK FACTOR; SQUAMOUS CELL CARCINOMA;

EID: 0030892955     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb02147.x     Document Type: Article

References (19)

1. Lewandowsky F, Lutz W. Ein Fall einer bisher nicht beschriebenen Hauterkrankung (Epidermodysplasia verruciformis). Arch Dermatol Syphilol (Dtsch) 1922; 141: 193-203.
2. Lutzner MA. Epidermodysplasia verruciformis: an autosomal recessive disease characterised by viral warts and skin cancer. Bull Cancer 1978; 65: 169-82.
3. Androphy EJ, Dvoretzky I, Lowry DR. X-linked inheritance of epidermodysplasia verruciformis: genetic and virological studies of a kindred. Arch Dermatol 1985; 121: 864-8.
4. Jablonska S, Orth G, Oplaek S et al. Oncogenic potential of human papilloma viruses in verruciformis. A counterpart of the Shope papilloma-carcinoma complex. Arch Geschwulstforsch 1983; 53: 207-15.
5. Shamanin V, Delius H, de Villers E-M. Development of a broad spectrum PCR assay for the papillomaviruses and it's application in screening lung cancer biopsies. J Gen Virol 1994; 75: 1149-56.
6. Pfister H. Human papillomaviruses and skin cancer. Semin Cancer Biol 1992; 3: 263-71.
7. Steger G, Olsewsky M, Stockfleth E, Pfister H. Prevalence of antibodies to human papilloma virus type in the human sera. J Virol 1990; 64: 4399-406.
8. Shamanin V, Glover M, Rausch C et al. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res 1994; 54: 4610-13.
9. Jong-Tieben LM, Berkhout RJM, Smits HL et al. High frequency of detection of epidermodysplasia verruciformis-associated human papillomavirus DNA in biopsies from malignant and premalignant skin lesions from renal transplant recipients. J Invest Dermatol 1995; 105: 367-71.
10. Reid TMS, Fraser NG, Kernohan IR. Generalized warts and immune deficiency. Br J Dermatol 1976; 95: 559-67.
11. Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995; 131: 1312-18.
12. Cooper KD, Androphy EJ, Lowy D, Katz S. Antigen presentation and T cell activation in epidermodysplasia. J Invest Dermatol 1990; 94: 769-76.
13. Tanigaki T, Kanda R, Yutsudo M et al. Epidemiological aspects of epidermodysplasia verruciformis in Japan. Jpn J Cancer Res 1986; 77: 896-900.
14. Vousden KH. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J 1993; 7: 872-9.
15. Jacyk WK, Subbuswamy SG. Epidermodysplasia verruciformis in Nigerians. Dermatologica 1979; 159: 256-65.
16. Jacyk WK, De Villers EM. Epidermodysplasia verruciformis in Africans. Int J Dermatol 1993; 32(11): 806-10.
17. Lutzner MA, Blanchet-Bardon C, Orth G. Clinical Observations, virologic studies and treatment trials in patients with epidermodysplasia verruciformis. A disease induced by human papillomaviruses. J Invest Dermatol 1984; 83: 185-255.
18. Kowalzick L, Mensing H. Failure of etretinate in epidermodysplasia verruciformis. Dermatologica 1986; 173: 75-8.
19. Kanerva LO, Johnasson E, Niemi KM et al. Epidermodysplasia verruciformis. Clinical and light and electron-microscopic observations during etretinate therapy. Arch Dermatol Res 1985; 278: 153-60.